miRagen Therapeutics Gets $41M

Boulder-based miRagen Therapeutics, the biopharmaceuticals firm led by William Marshall developing microRNA-based therapeutics, said Tuesday that it has raised $41M in a Series C funding round. The funding was co-led by MRL Ventures, the venture arm of Merck, along with JAFCO Co., and also included Brace Pharma Capital, MP Healthcare Venture Management, Atlas Venture, Boulder Ventures, Remeditex Ventures, Amgen Ventures and others. Joshua Resnick, M.D., president of MRL Ventures, will join the company's board with the funding. More information »